Abstract:Objective: To explore the clinical outcomes and characteristics of TP53-mutated primary myelodysplastic syndromes (MDS). Methods: A total of 74 de novo primary MDS patients who were diagnosed and treated in the Department of Hematology of our hospital from January 2018 and September 2021 were analyzed retrospectively. All patients had evaluable blood cell counts, mean corpuscular volume (MCV), lactate dehydrogenase (LDH), bone marrow (BM) morphology, biopsy, and MDS-related 20-gene mutations sequencing. In addition, 69 of 74 patients had complete cytogenetic analysis through conventional chromosome analysis and fluorescence in-situ hybridization. Results: Patients were divided into two cohorts, the TP53-mutated type (TP53Mut) group (n = 19) and TP53 wild type (TP53WT) group (n = 55). Compared with the TP53WT group, patients in the TP53Mut group had higher ratios of cytogenetic abnormalities (82.4% vs. 30.8%, P < 0.001), with 5q- karyotype (64.70% vs. 38.5%, P < 0.001), complex karyotype(CK) (64.70% vs. 38.5%, P < 0.001), HR-MDS (94.7% vs. 61.8%, P = 0.008), and acute myelogenous leukemia (AML) transformation (26.3% vs. 12.7%, P < 0.001). Interestingly, patients in the TP53Mut group had lower median MCV than the TP53WT group (94.40 fl vs. 101.90 fl, P = 0.008). Furthermore, MCV = 100 fl as cutoff, and found that MCV ≤ 100 fl was more common in the TP53Mut group (73.7% vs. 38.2%, P < 0.001). After 1-4 courses of HMA ± chemotherapy, the overall response rate of the TP53Mut group was higher than the TP53WT group (83.3% vs. 71.4%, P = 0.012). With the median follow-up 12.0 months (1-46 months), the results show that the median OS and leukemia-free survival (LFS) of TP53Mut group was significantly shorter than the TP53WT group (P = 0.0018; P = 0.0310). Results of multivariate Cox proportional hazard analyses show TP53 mutation was an independent prognostic factor for the OS (HR 2.724, 95%CI 1.099-6.750, P = 0.030). Conclusion: TP53-mutated primary MDS patients were associated with higher frequency of cytogenetic abnormalities, with 5q- karyotype, CK, AML transformation, higher risk IPSS-R, lower MCV and sensitive to HMA treatment, but worse survival.

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

TP53 mutation screening for patients at risk of myeloid malignancy

TP53 in MDS and AML: Biological and Clinical Advances.

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting

The Role of TP53 in Acute Myeloid Leukemia: Challenges and Opportunities

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms

TP53 in Myelodysplastic Syndromes

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia

TP53 signal pathway confers potential therapy target in acute myeloid leukemia

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

What have we learned about TP53- mutated acute myeloid leukemia?

Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia

Chemotherapy and Mismatch Repair Deficiency Cooperate to Fuel TP53 Mutagenesis and ALL Relapse

Deciphering TP53 mutant Cancer Evolution with Single-Cell Multi-Omics

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Elucidating the immune landscape and potential prognostic model in acute myeloid leukemia with TP53 mutation

p53 biology and reactivation for improved therapy in MDS and AML

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes